Catalent Selected to Provide Oral Delivery Systems

September 26, 2018

Applied Clinical Trials

GB Sciences, Inc. and Catalent Pharma Solutions, a global provider of delivery technologies and development solutions, announced that GB Sciences has selected Catalent to provide oral delivery systems, formulation development, and clinical-scale oral dose manufacturing of GB Sciences’ proprietary active pharmaceutical ingredients for its Parkinson’s disease therapies.

Read the full release here.

Related Content:

News